RESULTS UNDERPIN DCP-001’S POTENTIAL AS A NOVEL MAINTENANCE AND INTERVENTIONAL THERAPY IN A MAJOR SOLID TUMOR INDICATION
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical firm centered on immunotherapies addressing tumor recurrence, as we speak introduced the upcoming presentation of first medical knowledge from the continuing ALISON Phase I trial evaluating security and feasibility of its upkeep immunotherapy product candidate DCP-001 in ovarian most cancers.
The knowledge can be offered in an oral poster presentation on Thursday, October twenty seventh, 2022, at 2:50 pm CET on the European Society of Gynaecological Oncology (ESGO) 2022 Congress by Mendus’ collaboration companion, the Department of Obstetrics and Gynaecology of the University Medical Centre Groningen, The Netherlands. The summary relating to the information is out there on the ESGO website.
The preliminary knowledge demonstrates that DCP-001 was protected and well-tolerated, confirming the benign security profile of DCP-001 noticed in a number of accomplished and ongoing medical trials. This helps its suitability as a upkeep remedy and justifies continued improvement of this novel immunotherapy idea in ovarian most cancers, the deadliest gynaecological most cancers as a consequence of its excessive recurrence price.
The presentation on the ESGO Congress may even embrace new preclinical knowledge demonstrating the synergistic results of mixing DCP-001 vaccination with intratumoral immune priming. This novel therapeutic technique of mixing native and systemic intervention advantages from Mendus’ distinctive experience in each areas and resulted in a really potent suppression of tumor development, together with full tumor regressions in a humanized mouse mannequin for ovarian most cancers.
“The upcoming presentation at ESGO 2022 has important relevance for Mendus in a number of methods. First, the ALISON research is a vital step in direction of exploring strong tumor indications with DCP-001 and the potential improvement of a novel immunotherapy possibility in ovarian most cancers. Secondly, we’re for the primary time demonstrating the advantages of mixing vaccination and intratumoral priming, offering the premise for potential novel therapeutic approaches”, commented Erik Manting, PhD, Chief Executive Officer of Mendus. “While we’re awaiting key survival knowledge updates of the ADVANCE II trial in AML in This autumn, we additionally look ahead to reporting further knowledge within the coming months from our ovarian most cancers program, together with immunomonitoring knowledge investigating the immune responses by ovarian most cancers sufferers following administration of DCP-001.”
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
Telephone: +49 160 9352 9951
ABOUT MENDUS AB (PUBL)
Mendus is devoted to altering the course of most cancers remedy by addressing tumor recurrence and enhancing survival outcomes for most cancers sufferers, whereas preserving high quality of life. We are leveraging our unparalleled experience in allogeneic dendritic cell biology to develop a sophisticated medical pipeline of novel, off-the-shelf, cell-based immunotherapies which mix medical efficacy with a benign security profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm underneath the ticker IMMU.ST. http://www.mendus.com/
#Mendus #report #constructive #medical #preclinical #knowledge #ovarian #most cancers #European #Society #Gynaecological #Oncology #Congress